Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

• Toshihiko Matsumoto,
• Tatsuki Ikoma,
• Shogo Yamamura,
• Kou Miura,
• Takao Tsuduki,
• Takanori Watanabe,
• Hiroki Nagai,
• Masahiro Takatani,
• Hisateru Yasui

Affiliations

Toshihiko Matsumoto

Department of Clinical Oncology, Kobe City Medical Center General Hospital

Tatsuki Ikoma

Department of Clinical Oncology, Kobe City Medical Center General Hospital

Shogo Yamamura

Department of Clinical Oncology, Kobe City Medical Center General Hospital

Kou Miura

Department of Internal Medicine, Himeji Red Cross Hospital

Takao Tsuduki

Department of Internal Medicine, Himeji Red Cross Hospital

Takanori Watanabe

Department of Surgery, Himeji Red Cross Hospital

Hiroki Nagai

Department of Clinical Oncology, Kobe City Medical Center General Hospital

Masahiro Takatani

Department of Internal Medicine, Himeji Red Cross Hospital

Hisateru Yasui

Department of Clinical Oncology, Kobe City Medical Center General Hospital